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INTRODUCTION
Chemotherapy is one of the main treatment
options for relapsed esophageal cancer. Although
low dose FP therapy(combination of 5-fluorouracil
and cisplatin) is considered the most effective regi-
men, the patients require long-term hospitalization
and tend toward a remarkable loss of quality of life.
So development of the alternative chemotherapy
that can maintain both quality of life for the pa-
tients and effectiveness in the disease has been ex-
pected. We report a case of early relapsed esopha-
geal cancer successfully treated with outpatient S -1
(TS-1 )/cisplatin (CDDP) therapy following do-
cetaxel/5-fluorouracil (5-FU)/CDDP therapy in
hospital.
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The patient was a 55-year-old-male. He received
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subtotal esophagectomy for esophageal cancer
(pT1b, N0, M0, stage II) in April 2005. Histopa-
thological diagnosis was moderately differentiated
squamous cell carcinoma, sm, ly2, v0, and only one
lymph node metastasis was recognized in 106
recR. Therefore the postoperative diagnosis was
found to be pT1b, N1, M 0, stage II. As postop-
erative chemotherapy, the patient received monthly
DFP therapy (docetaxel 40mg/body, 5-FU 750mg/
body, CDDP 10mg/body : administered every four
weeks ) for 3 months with no problem. Six months
post operatively, the routine follow-up CT scan dem-
onstrated multiple tumor shadows in the bilateral
lungs (Fig. 1). All tumor markers indicated normal
values and further examinations showed no other
metastasis. Under the diagnosis of multiple recur-
rence of the esophageal cancer in the bilateral lungs,
the patient was hospitalized and planned to re-
ceive intensive chemotherapy.
Based on our first choice of chemotherapy for
recurrent esophageal cancer, the patient was hos-
pitalized and began to receive weekly DFP ther-
apy (docetaxel 40 mg/week:day1, 5 -FU 500mg/day:
days 1-5, CDDP 10 mg/day : days 1-5 ; continuous
administration for 4 weeks followed by rest for 2
weeks). After 2 weeks administration, grade 2
anorexia and grade 2 leukopenia appeared. Al-
though CT scan at this point showed slight reduc-
tion of the size of lung tumors (Fig. 2), the patient
eagerly hoped for outpatient treatment. After
informed consent, the treatment was changed to
outpatient chemotherapy with TS-1 100 mg/day
(continuous administration for 3 weeks followed
by 1 week rest) and CDDP 20mg/ every week. The
patient came to our hospital every week for blood
examination and the administration of CDDP. Al-
though grade 1 anorexia and grade 2 leukopenia
were observed, this treatment regimen allowed the
patient to continue working without interruption of
the weekly administration. During the course,
blood biochemistry did not show any abnormal
values.
Follow up CT showed the disappearance of the
all tumors 2 months after TS-1/CDDP chemother-
apy (Fig. 3). The administration of CDDP was
stopped 2 months after the disappearance of all
shadows, and the patient has continued to receive
only TS-1 100 mg/day (continuous administration
for 3 weeks followed by 1 week rest).
There were no obvious signs of recurrence 5
months after the chemotherapy. The clinical course
was described in Fig. 4.
Fig 2. CT finding after 2 weeks of DFP therapy showing slight
reduction in the size of lung tumors (arrows)
Fig 1. CT finding before chemotherapy demonstrated multiple
lung metastases in the bilateral lungs (arrows)
Fig 3. CT finding after 2 months TS -1/CDDP therapy showing
the disappearance of all tumors
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DISCUSSION
Because surgical treatments often can not
achieve a cure, chemotherapy or radiotherapy
plays a main role in the treatment of recurrent
esophageal cancer. While FP therapy has been
recognized as the standard chemotherapy for esopha-
geal cancer, some studies about chemotherapy
using taxane have examined and reported with
good results (1). From 2002, in our institution,
docetaxel/5 -FU/CDDP therapy (DFP therapy) has
been adopted as the first choice chemotherapy
for advanced or recurrent esophageal cancer.
Our patient also received monthly DFP therapy 3
times as postoperative outpatient treatment, but
multiple lung metastases appeared 6 months post-
operatively. For intensive chemotherapy, this case
was hospitalized and planned to receive weekly
DFP therapy. However, the patient eagerly hoped
for outpatient treatment during the middle of the
treatment period. So we had to consider an effective
chemotherapy that could be safely administrated
on an outpatient basis.
TS-1 is an oral medicine containing tegafur, gi-
meracil and oteracil potassium, and also reported
a superior anticancer effect compared to that of
uracil/tegafur (2). Regarding TS-1 based treatment
for esophageal cancer, TS-1/CDDP chemotherapy
or TS-1/CDDP with radiotherapy has been reported
to show good results (3-7). Hiraki et al . (8) have
reported the effectiveness of combination TS-1/
CDDP chemotherapy for multiple lung metasta-
ses. In those reports, CDDP was administered by
continuous intravenous drip infusion of 70 mg/m2
for 24 hours, or daily intravenous drip infusion of
10 mg/m2 for five consecutive days during which
the patient must be hospitalized. Sakaguchi et al .
(9) have reported a case responding remarkably
to TS-1/ weekly CDDP combination chemoradio-
therapy and described that administration of TS-1
and weekly CDDP 20 mg/m2 can be performed on
an outpatient basis. Our patient received intrave-
nous drip infusion of CDDP 20 mg/body each
week while continuing to keep on working without
severe side effects, and as a result, pulmonary me-
tastases disappeared successfully. Because ear-
lier administration of docetaxel might play some
roles in this remarkable outcome, further investi-
gation must be made on the biochemical relation
between docetaxel and TS-1/CDDP. Although our
patient has continued to receive TS-1 only for 3
months (Fig. 4), there have not been any obvious
signs of recurrence to date. Thus, TS-1 therapy
seems to be useful as maintenance therapy. The
TS-1/CDDP therapy in the outpatient is thought
to be an effective treatment contributing to main-
taining the quality of life for patients.
Fig 4. Clinical course
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